ReviewFrontiers in medicine2026
Artificial intelligence in non-small cell lung cancer: transforming diagnosis, treatment, and prognostic evaluation.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is characterized by profound biological heterogeneity, frequently leading to late-stage diagnosis, recurrence, or metastasis. Conventional clinical pathways heavily depend on subjective visual interpretations, invasive tissue biopsies, and experience-based medical models that constrain individualized precision medicine. Identifying noninvasive, cross-scale tools for whole-disease-course assessment is critical for optimizing clinical decision-making and survival outcomes. This review critically synthesizes recent research progress and core algorithmic applications of artificial intelligence (AI) across the diagnostic, therapeutic, and prognostic continuum of NSCLC. In diagnostics, AI models enable rapid morphological screening and tumor subtyping on digital pathology slides, whereas multimodal imaging radiomics extracts microscopic features from macroscopic CT, PET/CT, and MRI scans to noninvasively identify tumor heterogeneity and map metastatic risk. Therapeutically, machine learning and large language models predict treatment responses, characterize tumor microenvironment dynamics, optimize perioperative surgical strategies, and accelerate drug discovery by screening chemical databases and decoding candidate drug mechanisms. Prognostically, multiscale fusion models integrate liquid biopsies, pathomics, radiomics, and clinical records to provide precise risk stratification for recurrence and survival outcomes. While AI has demonstrated transformative potential across the entire clinical lifecycle of NSCLC, significant technical bottlenecks remain, including severe data heterogeneity across healthcare institutions, the lack of clinical transparency in end-to-end "black box" architectures, and low-throughput biological validation. Future research must focus on standardizing data protocols, improving explainable AI, and incorporating multidimensional time series data to realize true intelligent precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.